Chung CJ, et al. - Researchers used the ADAPT-DES registry to determine if high on-aspirin platelet reactivity (HAPR) increases risk of adverse outcomes following percutaneous coronary intervention (PCI). This registry included a total of 8,526 “all-comer” patients who had drug-eluting stents placed and were treated with aspirin and clopidogrel. Findings demonstrated infrequent HAPR in this large registry of patients undergoing PCI. Findings of 2-year follow-up revealed no association of HAPR with increased rates of major adverse cardiac events (MACE), stent thrombosis, myocardial infarction, or all-cause mortality. Propensity-adjusted multivariable analyses showed MACE after successful PCI was not independently predicted by HAPR. No association of HAPR with reduced bleeding was found. Nor it was found to be related to worse ischemic outcomes, even in patients with concomitant high on-clopidogrel platelet reactivity. Overall, no clear association between HAPR and 2-year clinical outcomes was evident.